Medivation (NASDAQ:MDVN) had its price target upped by Maxim Group from $66.00 to $71.00 in a research note issued to investors on Monday, AnalystRatingsNetwork.com reports. The firm currently has a buy rating on the stock.
MDVN has been the subject of a number of other recent research reports. Analysts at Aegis reiterated a buy rating on shares of Medivation in a research note to investors on Tuesday, October 22nd. Separately, analysts at Chardan Capital initiated coverage on shares of Medivation in a research note to investors on Wednesday, September 18th. They set a buy rating and a $72.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Medivation from an outperform rating to a neutral rating in a research note to investors on Wednesday, August 28th. They now have a $59.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $66.17.
In other Medivation news, Insider Cheryl Cohen unloaded 50,000 shares of the company’s stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $64.25, for a total value of $3,212,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Medivation (NASDAQ:MDVN) traded down 2.97% on Monday, hitting $62.00. 180,401 shares of the company’s stock traded hands. Medivation has a 1-year low of $41.89 and a 1-year high of $59.86. The stock’s 50-day moving average is $57.49 and its 200-day moving average is $52.09. The company’s market cap is $4.663 billion.
Medivation (NASDAQ:MDVN) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.14. The company had revenue of $70.15 million for the quarter, compared to the consensus estimate of $59.35 million. During the same quarter last year, the company posted ($0.15) earnings per share. Medivation’s revenue was up 63.5% compared to the same quarter last year. On average, analysts predict that Medivation will post $-0.90 earnings per share for the current fiscal year.
Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.